Immunotherapy vs Chemotherapy: A Comparative Look at Cancer Treatment

Cancer remains one of the most challenging diseases, with numerous treatment strategies aimed at improving patient outcomes. Chemotherapy has been a traditional method for decades, while immunotherapy has emerged as a promising alternative. Both treatments have their strengths, weaknesses, and unique mechanisms of action but let us dig into what makes them different and how it all works.

What is Chemotherapy?

Chemotherapy is one of the most well-known cancer treatments, using drugs to kill fast-growing cancer cells. These drugs target not only cancer cells but also healthy cells that divide rapidly, which is why side effects are often significant. Common side effects include hair loss, fatigue, nausea, and a weakened immune system.

Chemotherapy’s ability to treat various types of cancer is well-documented. However, its non-specific nature often leads to collateral damage in healthy tissues, resulting in severe side effects and reduced quality of life. Despite these drawbacks, it remains a cornerstone in the fight against cancer, especially for aggressive cancers that need immediate intervention.

Immunotherapy: The Body’s Defence System at Work

Unlike chemotherapy, which directly attacks cancer cells, immunotherapy harnesses the body’s own immune system to fight cancer. By stimulating or modifying the immune system, immunotherapy enables the body to recognize and destroy cancer cells more effectively. There are different types of immunotherapy, including checkpoint inhibitors, CAR T-cell therapy, and cancer vaccines.

Checkpoint inhibitors, such as Pembrolizumab (Keytruda), block proteins that prevent immune cells from attacking cancer cells. Research has shown significant success with checkpoint inhibitors in treating melanoma and non-small cell lung cancer (NSCLC). A study published in ‘The New England Journal of Medicine’ demonstrated that immunotherapy was more effective than chemotherapy in treating advanced melanoma, with a higher overall survival rate (Robert et al., 2015).

Effectiveness: Head-to-Head

Both treatments have their areas of success, but their effectiveness depends on the type of cancer being treated. Chemotherapy is most effective for rapidly growing cancers, where the cells are dividing quickly, such as leukaemia and certain types of breast cancer. Immunotherapy, on the other hand, is more effective in cancers with high mutational loads, like melanoma, because these cancers produce more abnormal proteins that the immune system can detect and attack.

A landmark study in ‘The Lancet Oncology’ compared the effectiveness of immunotherapy and chemotherapy in NSCLC patients. The results showed that patients who received immunotherapy had a longer median survival time compared to those who received chemotherapy alone (Gandhi et al., 2018).

Once again, cancer is not a one size fits all and it’s quite likely that these treatments may not be effective for all, being different from cancer to cancer and fighter to fighter.

Side Effects: The Battle Beyond Cancer Cells

One of the significant downsides of chemotherapy is its broad spectrum of side effects, which include not only physical but also emotional and psychological effects. Immunotherapy also has side effects, but they tend to be different. While chemotherapy can weaken the immune system, immunotherapy can sometimes overstimulate it, leading to autoimmune reactions where the immune system attacks healthy tissues.

A 2019 study published in ‘Cancer Immunology Research’ found that while immunotherapy patients experienced fewer severe side effects, they were at risk of immune-related adverse events, such as colitis, hepatitis, and thyroiditis (Postow et al., 2019). This highlights the importance of careful monitoring in both therapies.

Cost and Accessibility

Chemotherapy is widely available and has been the standard treatment for many decades, which makes it more accessible in many parts of the world. Immunotherapy, being a newer form of treatment, is often more expensive and less available. According to a 2020 study by ‘JAMA Oncology’, the cost of immunotherapy can be substantially higher, with many treatments exceeding $100,000 annually (Patel et al., 2020). This raises concerns about the accessibility of immunotherapy for patients in low- and middle-income countries.

The Future: Combining Forces?

Recent research suggests that combining chemotherapy with immunotherapy may offer the best outcomes for some types of cancer. By using chemotherapy to shrink tumours and immunotherapy to boost the immune response, doctors hope to improve survival rates. A study published in *The New England Journal of Medicine* found that combining these treatments for patients with lung cancer improved overall survival compared to chemotherapy alone (Hellmann et al., 2018).

Both immunotherapy and chemotherapy have proven to be effective in treating cancer, but their suitability depends on the individual patient and the type of cancer. Chemotherapy offers a more immediate response but comes with significant side effects, while immunotherapy represents a more targeted, long-term approach but can be costly and trigger autoimmune responses. As research continues, we may see a future where these treatments are used in tandem, providing better outcomes with fewer side effects.

Reference list

1. Robert, C., et al. (2015). "Pembrolizumab versus Ipilimumab in Advanced Melanoma." *The New England Journal of Medicine*, 372(26), 2521-2532.

2. Gandhi, L., et al. (2018). "Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer." *The Lancet Oncology*, 19(1), 65-75.

3. Postow, M. A., et al. (2019). "Immune-Related Adverse Events Associated with Immune Checkpoint Blockade." *Cancer Immunology Research*, 7(10), 1280-1285.

4. Patel, J. D., et al. (2020). "Cost of Immunotherapy for Cancer." *JAMA Oncology*, 6(4), 583-592.

5. Hellmann, M. D., et al. (2018). "Nivolumab plus Ipilimumab in Advanced Non–Small-Cell Lung Cancer." *The New England Journal of Medicine*, 378(21), 2093-2104.

 

x